Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Vacca, M; Kamzolas, I; Harder, LM; Oakley, F; Trautwein, C; Hatting, M; Ross, T; Bernardo, B; Oldenburger, A; Hjuler, ST; Ksiazek, I; Lindén, D; Schuppan, D; Rodriguez-Cuenca, S; Tonini, MM; Castañeda, TR; Kannt, A; Rodrigues, CMP; Cockell, S; Govaere, O; Daly, AK; Allison, M; de Lichtenberg, KH; Kim, YO; Lindblom, A; Oldham, S; Andréasson, AC; Schlerman, F; Marioneaux, J; Sanyal, A; Afonso, MB; Younes, R; Amano, Y; Friedman, SL; Wang, S; Bhattacharya, D; Simon, E; Paradis, V; Burt, A; Grypari, IM; Davies, S; Driessen, A; Yashiro, H; Pors, S; Andersen, MW; Feigh, M; Yunis, C; Bedossa, P; Stewart, M; Cater, HL; Wells, S; Schattenberg, JM; Anstee, QM; Tiniakos, D; Perfield, JW; Petsalaki, E; Davidsen, P; Vidal-Puig, A; Anstee, QM; Daly, AK; Cockell, S; Tiniakos, D; Bedossa, P; Burt, A; Oakley, F; Cordell, HJ; Day, CP; Wonders, K; Missier, P; McTeer, M; Vale, L; Oluboyede, Y; Breckons, M; Boyle, J; Bossuyt, PM; Zafarmand, H; Vali, Y; Lee, J; Nieuwdorp, M; Holleboom, AG; Angelakis, A; Verheij, J; Ratziu, V; Clément, K; Patino-Navarrete, R; Pais, R; Paradis, V; Schuppan, D; Schattenberg, JM; Surabattula, R; Myneni, S; Kim, YO; Straub, BK; Vidal-Puig, A; Vacca, M; Rodrigues-Cuenca, S; Allison, M; Kamzolas, I; Petsalaki, E; Campbell, M; Lelliott, CJ; Davies, S; Oresic, M; Hyötyläinen, T; McGlinchey, A; Mato, JM; Millet, O; Dufour, JF; Berzigotti, A; Masoodi, M; Lange, NF; Pavlides, M; Harrison, S; Neubauer, S; Cobbold, J; Mozes, F; Akhtar, S; Olodo-Atitebi, S; Banerjee, R; Shumbayawonda, E; Dennis, A; Andersson, A; Wigley, I; Romero-Gómez, M; Gómez-González, E; Ampuero, J; Castell, J; Gallego-Durán, R; Fernández-Lizaranzu, I; Montero-Vallejo, R; Karsdal, M; Rasmussen, DGK; Leeming, DJ; Sinisi, A; Musa, K; Sandt, E; Tonini, MM; Bugianesi, E; Rosso, C; Armandi, A; Marra, F; Gastaldelli, A; Svegliati, G; Boursier, J; Francque, S; Vonghia, L; Verrijken, A; Dirinck, E; Driessen, A; Ekstedt, M; Kechagias, S; Yki-Järvinen, H; Porthan, K; Arola, J; van Mil, S; Papatheodoridis, G; Cortez-Pinto, H; Silva, AP; Rodrigues, CMP; Valenti, L; Pelusi, S; Petta, S; Pennisi, G; Miele, L; Liguori, A; Geier, A; Rau, M; Trautwein, C; Reissing, J; Aithal, GP; Francis, S; Palaniyappan, N; Bradley, C; Hockings, P; Schneider, M; Newsome, PN; Hübscher, S; Wenn, D; Magnanensi, J; Trylesinski, A; Mayo, R; Alonso, C; Duffin, K; Perfield, JW; Chen, Y; Hartman, ML; Yunis, C; Miller, M; Chen, Y; McLeod, EJ; Ross, T; Bernardo, B; Schölch, C; Ertle, J; Younes, R; Coxson, H; Simon, E; Gogain, J; Ostroff, R; Alexander, L; Biegel, H; Kjær, MS; Harder, LM; Al-Sari, N; Veidal, SS; Oldenburger, A; Ellegaard, J; Balp, MM; Jennings, L; Martic, M; Löffler, J; Applegate, D; Torstenson, R; Lindén, D; Fournier-Poizat, C; Llorca, A; Kalutkiewicz, M; Pepin, K; Ehman, R; Horan, G; Ho, G; Tai, D; Chng, E; Xiao, T; Patterson, SD; Billin, A; Doward, L; Twiss, J; Thakker, P; Derdak, Z; Yashiro, H; Landgren, H; Lackner, C; Gouw, A; Hytiroglou, P; Govaere, O; Brass, C.
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
NAT METAB. 2024; 6(6): 1178-+.
Doi: 10.1038/s42255-024-01043-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Lackner Karoline
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD 'human proximity score' to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline- deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.